Clinical trial
Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma
NCT00193544 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00193544 |
|---|---|
| Title | Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma |
| Official title | Phase II Trial of Arsenic Trioxide and Thalidomide in the Treatment of Patients With Refractory Multiple Myeloma |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | CTI BioPharma Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Arsenic Trioxide, Thalidomide |
| Enrollment | 40 |
| Start date | Mar 1, 2002 |
| Primary completion | Oct 1, 2005 |
| Completion | Jan 1, 2009 |
| First posted | Sep 19, 2005 |
| Last update posted | Jan 23, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: